This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
|Articles|March 23, 2022
Daily Medication Pearl: Octreotide (Sandostatin)
Author(s)Saro Arakelians, PharmD
Advertisement
Medication Pearl of the Day: Octreotide (Sandostatin)
Indications: Sandostatin is a somatostatin analogue indicated to treat severe diarrhea and flushing associated with certain types of metastatic carcinoid tumors. The drug is also used to treat acromegaly.
Insight:
- Dosing: 50 mcg 3 times daily, Sandostatin injection subcutaneously for 2 weeks followed by 20 mg intragluteally every 4 weeks for 3 months.
- Dosage forms: For injectable suspension, strengths 10 mg per 6 mL, 20 mg per 6 mL, or 30 mg per 6 mL vials.
- Adverse events: The most common adverse reactions, occurring in ≥ 20% of patients are diarrhea, cholelithiasis, abdominal pain, flatulence, back pain, fatigue, headache, abdominal pain, nausea, and dizziness.
- Mechanism of action: Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses LH response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide.
- Manufacturer: Novartis
Sources:
Advertisement
Related to this article
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Ali A. Habib, MD, discusses how NIMBLE’s hospitalization findings complement symptom outcomes for investigational cemdisiran and highlights pharmacists’ role in vaccination tracking and infection-risk counseling.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
2
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
3
Dostarlimab Receives FDA Accelerated Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
4
FDA Approves Phentolamine Eye Drop for Presbyopia in Adults
5